The present study demonstrates that AMPK and subsequent downstream effects can be activated by both an indirect (metformin) and direct (compound 991) activator of AMPK in skeletal muscle cells from patients with ME/CFS. Here, PRKAA1 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.